CGON

CG Oncology, Inc.

NasdaqGSUSDEQUITY DELAYED

79.81

▲ 2.20 (2.83%)

MARKET · —

Price

Open

79.49

Prev close

77.61

Day high

79.89

Day low

77.38

Volume

627.41K

Market cap

—

P/E (TTM)

—

52W range

25.25 – 80.97

Trailing performance

Price return · vs SPY

Returnvs SPY

+6.37% +7.7%

+12.22% +8.5%

+23.56% +20.5%

+38.49% +27.4%

YTD

+92.22% +79.9%

+212.61% +192.6%

— -74.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

77.18

+3.40% from price

SMA 20

74.71

+6.82% from price

SMA 50

71.03

+12.36% from price

SMA 100

68.23

+16.97% from price

SMA 200

59.26

+34.69% from price

EMA 12

76.70

+4.06% from price

EMA 26

74.43

+7.23% from price

EMA 50

71.76

+11.21% from price

RSI (14)

61.1

Neutral

MACD (12,26,9)

2.27

Hist 0.33

ATR (14)

3.02

3.78% of price

Realised vol 30D

49.5%

Annualised

Bollinger upper

80.91

20, 2σ

Bollinger lower

68.51

20, 2σ

50 / 200 cross

Golden

71.03 vs 59.26

Trend bias

Above 200

+34.69%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.17

More volatile than market

Correlation to SPY

0.26

Largely independent

Realised vol 30D

49.5%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-27.4%

Peak to trough

Max drawdown 5Y

-67.5%

Peak to trough

ATR 14

3.02

3.78% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 79.81

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

CGON · links out to the publisher

BofA Adjusts Price Target on CG Oncology to $88 From $87 MT Newswires · 15d ago RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating MT Newswires · 15d ago CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates Zacks · 16d ago CG Oncology Q2 Net Loss Widens MT Newswires · 16d ago CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire · 16d ago Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Renewed Pressure on Semiconductor Stocks MT Newswires · 25d ago CG Oncology Phase 3 Study Shows Durable Responses in High-Risk Bladder Cancer MT Newswires · 25d ago CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology GlobeNewswire · 26d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.